Last reviewed · How we verify
Stillen
At a glance
| Generic name | Stillen |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration (PHASE2)
- Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis (PHASE3)
- A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab. (PHASE4)
- Efficacy of DA-5204 on Gastroesophageal Reflux Disease (PHASE3)
- To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients (PHASE3)
- Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients (PHASE4)
- A Study to Evaluate the Efficacy and Safety of DA-5204 (PHASE3)
- A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stillen CI brief — competitive landscape report
- Stillen updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI